Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CLS010
MIFTS: 42

Cluster Headache

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cluster Headache

About this section

MalaCards integrated aliases for Cluster Headache:

Name: Cluster Headache 52 36 54 71

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Neuronal diseases Eye diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

KEGG 36 H01588
ICD10 32 G44.0
UMLS 71 C0009088
Sources

Summaries for Cluster Headache

About this section
NIH Rare Diseases : 52 Cluster headaches are a form of headache notable for their extreme pain and their pattern of occurring in "clusters", usually at the same time(s) of the day for several weeks. The headaches are accompanied by autonomic symptoms, and some people experience restlessness and agitation. A cluster headache begins with severe pain strictly on one side of the head, often behind or around one eye. In some people, it may be preceded by a migraine-like "aura." The pain usually peaks over the next 5 to 10 minutes, and then continues at that intensity for up to three hours before going away. Typical attacks may strike up to eight times a day and are relatively short-lived. On average, a cluster period lasts 6 to 12 weeks. Autonomic symptoms may include: conjunctival injection (bloodshot eyes), swelling under or around the eye, excessive tearing of the eyes, drooping of the eyelid, runny nose and/or nasal congestion, and forehead and facial sweating. These symptoms generally occur only during the pain attack and are on the same side as the headache pain. Cluster headaches usually begin between the ages of 20 and 50, although they can start at any age. Males are more commonly affected than females. Treatment can be divided into acute therapy aimed at stopping symptoms once they have started and preventive therapy aimed at preventing recurrent attacks during the cluster period.

MalaCards based summary : Cluster Headache is related to headache and sleep disorder, and has symptoms including headache and recurrent paroxysmal headache. An important gene associated with Cluster Headache is HCRTR2 (Hypocretin Receptor 2), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Betamethasone and Rizatriptan have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and hypothalamus.

KEGG : 36 Cluster headache (CH) is the commonest of the trigeminal autonomic cephalalgias (TAC) characterized by attacks of severe, strictly unilateral pain, which is orbital, supraorbital, temporal, or in any combination of these sites, with duration of pain attacks of 15 to 180 min. The pain of CH is associated with ipsilateral conjunctival injection, lacrimation, nasal congestion, rhinorrhea, forehead and facial sweating, miosis, ptosis and/or eyelid edema, and/or restlessness or agitation. Headaches often recur at the same time each day during the cluster period, which can last for weeks to months. CH occurs more commonly in male patients (2.5:1 to 4.3:1 male to female) with an average age of onset in the third or fourth decade. The pathophysiology of CH is not fully understood, but may include a genetic component. Treatment focuses on avoiding triggers and includes abortive therapies, prophylaxis during the cluster period, and long-term treatment in patients with chronic CH. Evidence supports the use of supplemental oxygen, sumatriptan, and zolmitriptan for acute treatment of episodic CH. Verapamil is used to treat chronic CH. More invasive treatments, including nerve stimulation and surgery, may be helpful in refractory cases.

Wikipedia : 74 Cluster headache (CH) is a neurological disorder characterized by recurrent severe headaches on one side... more...

Sources

Related Diseases for Cluster Headache

About this section

Diseases in the Cluster Headache family:

Cluster Headache, Familial

Diseases related to Cluster Headache via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Related Disease Score Top Affiliating Genes
1 headache 33.2 CALCA CACNA1A
2 sleep disorder 30.0 HCRTR2 CLOCK
3 familial hemiplegic migraine 30.0 CALCA CACNA1A
4 paine syndrome 29.9 PNOC CALCA
5 migraine with aura 29.8 VIP CALCA CACNA1A
6 drug dependence 29.2 PNOC ADH4
7 migraine with or without aura 1 29.1 VIP PNOC HCRTR2 CALCA CACNA1A ADCYAP1
8 cluster headache, familial 12.8
9 paroxysmal hemicrania 11.9
10 hemicrania continua 11.1
11 trigeminal neuralgia 10.5
12 ptosis 10.5
13 migraine without aura 10.4
14 horner's syndrome 10.4
15 sleep apnea 10.3
16 autonomic dysfunction 10.3
17 trigeminal autonomic cephalalgia 10.3
18 carotid artery dissection 10.2
19 head injury 10.2
20 meningioma, radiation-induced 10.2
21 meningioma, familial 10.2
22 spinal meningioma 10.2
23 secretory meningioma 10.2
24 lymphoplasmacyte-rich meningioma 10.2
25 chronic pain 10.2
26 advanced sleep phase syndrome 10.1 HCRTR2 CLOCK
27 anxiety 10.1
28 angina pectoris 10.1
29 arteriovenous malformation 10.1
30 cerebrovascular disease 10.1
31 peptic ulcer disease 10.1
32 rare headache 10.1
33 anisocoria 10.0
34 myositis 10.0
35 kearns-sayre syndrome 10.0
36 tolosa-hunt syndrome 10.0
37 generalized anxiety disorder 10.0
38 orbital plasma cell granuloma 10.0
39 sunct headache 10.0
40 depression 10.0
41 paresthesia 10.0
42 syncope 10.0
43 tremor 10.0
44 hemiplegia 10.0 CALCA CACNA1A
45 detrusor sphincter dyssynergia 10.0 CALCA ADCYAP1
46 alternating hemiplegia of childhood 10.0 CALCA CACNA1A
47 pain agnosia 10.0 PNOC CALCA
48 agnosia 10.0 PNOC CALCA
49 hypocalcemia, autosomal dominant 1 10.0 CALCA ADH4
50 multiple sclerosis 10.0

Graphical network of the top 20 diseases related to Cluster Headache:



Diseases related to Cluster Headache
Sources

Symptoms & Phenotypes for Cluster Headache

About this section

UMLS symptoms related to Cluster Headache:


headache, recurrent paroxysmal headache
Sources

Drugs & Therapeutics for Cluster Headache

About this section

Drugs for Cluster Headache (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
2
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Ethanol Approved Phase 4 64-17-5 702
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
11
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
14
Topiramate Approved Phase 4 97240-79-4 5284627
15
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
16 Anti-Infective Agents Phase 4
17 Oxazolidinones Phase 4
18 Respiratory System Agents Phase 4
19 Anti-Asthmatic Agents Phase 4
20 Serotonin 5-HT1 Receptor Agonists Phase 4
21 Serotonin Receptor Agonists Phase 4
22 Neurotransmitter Agents Phase 4
23 Hormones Phase 4
24 Anti-Arrhythmia Agents Phase 4
25 Sodium Channel Blockers Phase 4
26 Diuretics, Potassium Sparing Phase 4
27 Hormone Antagonists Phase 4
28 Methylprednisolone Acetate Phase 4
29 Antineoplastic Agents, Hormonal Phase 4
30 Neuroprotective Agents Phase 4
31 Antiemetics Phase 4
32 Protective Agents Phase 4
33 Gastrointestinal Agents Phase 4
34 glucocorticoids Phase 4
35 Anti-Inflammatory Agents Phase 4
36 Triamcinolone diacetate Phase 4
37 Triamcinolone hexacetonide Phase 4
38 triamcinolone acetonide Phase 4
39 Anesthetics Phase 4
40 Anesthetics, Local Phase 4
41 BB 1101 Phase 4
42 Hypoglycemic Agents Phase 4
43 Anticonvulsants Phase 4
44
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
45
Sodium oxybate Approved Phase 3 502-85-2 5360545
46
Sumatriptan Approved, Investigational Phase 3 103628-46-2 5358
47
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
48
Zolmitriptan Approved, Investigational Phase 2, Phase 3 139264-17-8 441240 60857
49 Cortivazol Investigational Phase 2, Phase 3 1110-40-3
50 Anesthetics, General Phase 3

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Zolmitriptan by Sublingual Administration in the Treatment of Cluster Headache: A Multi-center Randomized Cross-controlled Trial Unknown status NCT03377257 Phase 4 zolmitriptan by sublingual administration;zolmitriptan by oral
2 4mg StatDose Imitrex for Acute Treatment of Cluster Headache Unknown status NCT00399243 Phase 4 Sumatriptan 4mg Statdose injection
3 Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study Unknown status NCT02686983 Phase 4 Betamethasone and local anesthetic
4 A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms. Completed NCT00753311 Phase 4 rizatriptan or placebo
5 Greater Occipital Nerve Block for Migraine Prophylaxis Completed NCT00915473 Phase 4 bupivicaine;normal saline;methylprednisolone;lidocaine
6 A Phase IV Single Blind Placebo-controlled Cross Over Study to Investigate the Efficacy of Greater Occipital Nerve Block With Local Anesthetic and Steroid in Patients With Chronic Migraine Completed NCT04017741 Phase 4 Combined Depo-Medrone and Lidocaine;Sodium Chloride 0.9% Inj
7 GON-injection for a Sooner and Better Treatment of Cluster Headache: a Double-blind Randomized Controlled Trial Recruiting NCT04014634 Phase 4 Methylprednisolone
8 A Comparison of Dexamethasone and Triamcinolone in Combination With Bupivacaine for Ultrasound-guided Occipital C2 Nerve Blocks: A Randomized Controlled Trial Recruiting NCT02655523 Phase 4 Triamcinolone;Dexamethasone;Normal Saline;Bupivacaine
9 Atrioventricular Block and Cluster Headache Not yet recruiting NCT04406259 Phase 4 Verapamil
10 A Single-Center, Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Topiramate in the Treatment of Subjects With Episodic or Chronic Cluster Headache. Terminated NCT00203190 Phase 4 Topiramate
11 Safety and Efficacy of Sodium Oxybate in the Prophylaxis of Headache and Sleep Disturbances in Patients With Chronic and Episodic Cluster Headache Unknown status NCT02637648 Phase 3 Sodium Oxybate;Placebo
12 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache Completed NCT02438826 Phase 3 Galcanezumab 300 mg;Placebo
13 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache Completed NCT00033839 Phase 3 Civamide (Zucapsaicin)
14 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache Completed NCT02397473 Phase 3 Galcanezumab;Placebo
15 Imigran STATdose - Japan Clinical Experience Study for Self-injection Completed NCT00356603 Phase 3 Sumatriptan Succinate
16 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache Completed NCT00069082 Phase 3 Civamide (Zucapsaicin);Sodium Chloride
17 A Double Blind Randomized Controlled Trial of Greater Occipital Nerve Infiltration in Cluster Headache Completed NCT00804895 Phase 2, Phase 3 ALTIM, cortivazol injections;PROAMP, subcutaneous serum physiological saline;Verapamil
18 Anodal Transcranial Direct Stimulation (tDCS) of the Anterior Cingulate Gyrus for the Treatment of Chronic Cluster Headache: a Pilot Trial. Completed NCT02462395 Phase 2, Phase 3
19 Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache Completed NCT01151631 Phase 3
20 Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Recruiting NCT03944876 Phase 3 Botulinum toxin type A;placebo
21 A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache Active, not recruiting NCT02797951 Phase 3 Galcanezumab
22 Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches Active, not recruiting NCT04066023 Phase 2, Phase 3 C213 Microneedle System;Placebo
23 A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Headache Period Not yet recruiting NCT01341548 Phase 3 Civamide nasal solution 0.01%
24 A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache Terminated NCT02964338 Phase 3 Fremanezumab;Placebo
25 A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache Terminated NCT03107052 Phase 3 Fremanezumab
26 A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Epidosic Cluster Headache Terminated NCT02945046 Phase 3 Fremanezumab;Placebo
27 Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache Unknown status NCT00274170 Phase 1, Phase 2 Octreotide
28 Endoscopic Block of the Sphenopalatine Ganglion With Botulinum Toxin in Intractable Cluster Headache - Safety Issues Completed NCT02019017 Phase 1, Phase 2 Botulinum Toxin Type A 25 IU;Botulinum Toxin Type A 50 IU
29 Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study Completed NCT00184587 Phase 2 candesartan cilexetil;placebo
30 Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues Completed NCT03066635 Phase 1, Phase 2 Botulinum Toxin Type A 25 IU;Botulinum Toxin Type A 12.5 IU
31 A Randomized, Multicenter Study for the Prevention and Acute Treatment of Chronic Cluster Headache Using Gammacore, Versus Standard of Care. Completed NCT01701245 Phase 2
32 Multicenter Feasibility Study of the Bion for Occipital Nerve Stimulation for Treatment of Chronic Headaches Completed NCT00205894 Phase 1, Phase 2
33 Proof of Concept Study for Evaluation of the Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache Recruiting NCT04179266 Phase 1, Phase 2 Ketamine
34 Safety and Efficacy of Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache: a Randomized, Double-blind, Placebo-controlled Phase II Study Recruiting NCT03781128 Phase 2 Lysergic Acid Diethylamide;Placebo
35 Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study Recruiting NCT04280055 Phase 1, Phase 2 Psilocybin
36 A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 Subcutaneous (s.c.) Terminated NCT02619617 Phase 2 SOM230;Placebo
37 A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prophylaxis of Episodic Cluster Headache Terminated NCT02209155 Phase 2 R-verapamil 75 mg tablet;Placebo
38 An Open Label, Pilot Study Evaluating the Efficacy and Safety of the Use of Nasal Carbon Dioxide for the Treatment of Episodic Cluster Headache Terminated NCT02381795 Phase 2 Nasal Carbon Dioxide
39 Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders Recruiting NCT02981173 Phase 1 0.143 mg/kg Psilocybin or 10 mg Psilocybin;0.0143 mg/kg Psilocybin or 1 mg Psilocybin;Placebo
40 The Pain Biomarker Study: Changes in Circulating Pain Signalling Molecules With Activation of Pain Receptors Active, not recruiting NCT03511846 Phase 1 Oral capsaicin;Topical capsaicin;Intranasal capsaicin;Low Flow Oxygen;High Flow Oxygen
41 Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Not yet recruiting NCT04353505 Phase 1 Ketorolac;Dexamethasone
42 A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache Terminated NCT01298921 Phase 1 Oxygen;Oxygen
43 Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache Unknown status NCT02168764
44 Pathway CH S&E Registry: Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache - ATI Neurostimulation System is Branded Internationally as Pulsante™ Microstimulator System Unknown status NCT02440776
45 CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients Unknown status NCT02466334 Calcitonin-Gene Related Peptide;Placebo
46 Effectiveness of Physiotherapy Program in Patients With Cluster Headache Unknown status NCT02460003
47 Study of the Cerebral Metabolism in Patients With Refractory Chronic Cluster Headache Treated by Occipital Nerve Stimulation Unknown status NCT02081482
48 Cluster Headache (CH), Addictions and Vascular Function Unknown status NCT02640105
49 French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders Unknown status NCT01842763
50 DBS of the Third Ventricle for Cluster Headache and Obesity Completed NCT02782533

Search NIH Clinical Center for Cluster Headache

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyproheptadine
Cyproheptadine hydrochloride
CYPROHEPTADINE HYDROCHLORIDE MONOHYDRATE
Dihydroergotamine
ergoloid mesylates, USP
Ergotamine
Oxygen
Sumatriptan
Sumatriptan Succinate
Sources

Genetic Tests for Cluster Headache

About this section
Sources

Anatomical Context for Cluster Headache

About this section

MalaCards organs/tissues related to Cluster Headache:

40
Brain, Eye, Hypothalamus, Testes, Pituitary, Heart, Spinal Cord
Sources

Publications for Cluster Headache

About this section

Articles related to Cluster Headache:

(show top 50) (show all 2856)
# Title Authors PMID Year
1
Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. 61 54
19330286 2009
2
Haplotype analysis confirms the association between the HCRTR2 gene and cluster headache. 61 54
18399985 2008
3
Investigation of neuromuscular transmission in some rare types of migraine. 54 61
17919307 2007
4
Association between migraine and the G1246A polymorphism in the hypocretin receptor 2 gene. 54 61
17883525 2007
5
CGRP-receptor antagonism in migraine treatment. 54 61
17691979 2007
6
Association between the G1246A polymorphism of the hypocretin receptor 2 gene and cluster headache: a meta-analysis. 61 54
17563843 2007
7
The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. 54 61
17376114 2007
8
Serotonin receptor ligands: treatments of acute migraine and cluster headache. 54 61
17087122 2007
9
Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene. 61 54
16554494 2006
10
Neurobiology in primary headaches. 61 54
15914251 2005
11
New targets in the acute treatment of headache. 61 54
15891413 2005
12
Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. 54 61
15867953 2005
13
Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. 61 54
16392873 2005
14
A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. 54 61
15477554 2004
15
Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. 54 61
15265049 2004
16
Circulating nociceptin levels during the cluster headache period. 61 54
15030536 2004
17
New therapeutic target in primary headaches - blocking theCGRP receptor. 54 61
12783573 2003
18
Calcitonin gene-related peptide (CGRP) in cerebrovascular disease. 61 54
12805934 2002
19
CACNA1A gene polymorphisms in cluster headache. 54 61
11843866 2001
20
No involvement of the calcium channel gene (CACNA1A) in a family with cluster headache. 54 61
11843867 2001
21
No involvement of the calcium channel gene (CACNA1A) in a family with cluster headache. 61 54
11843863 2001
22
[Both neurogenic and vascular causes of primary headache]. 54 61
11680150 2001
23
Sensory nerves in man and their role in primary headaches. 61 54
11595008 2001
24
Pathophysiology of primary headaches. 61 54
11252141 2001
25
Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. 61 54
11087777 2000
26
A pathophysiological view of primary headaches. 61 54
11200801 2000
27
A possible role for saliva as a diagnostic fluid in patients with chronic pain. 54 61
9662753 1998
28
Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients. 61 54
9117375 1997
29
Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. 54 61
7540279 1995
30
Neuropeptides in the cerebral circulation: relevance to headache. 61 54
7585922 1995
31
Neuropeptides in migraine and cluster headache. 61 54
7828188 1994
32
Nostril capsaicin application as a model of trigeminal primary sensory neuronal activation. 54 61
7520365 1994
33
PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache? 61
32142016 2020
34
A prospective case series of sphenopalatine ganglion pulsed radiofrequency therapy for refractory chronic cluster headache. 61
32065436 2020
35
Chronic pain and psychedelics: a review and proposed mechanism of action. 61
32371500 2020
36
Polygenic risk scores indicates genetic overlap between peripheral pain syndromes and chronic postsurgical pain. 61
32377986 2020
37
Cotard parasomnia: le délire de negation that occur during the sleep-wake dissociation? 61
32195661 2020
38
New insights in post-traumatic headache with cluster headache phenotype: a cohort study. 61
32381638 2020
39
S100B and NSE in Cluster Headache - Evidence for Glial Cell Activation? 61
32548854 2020
40
Neuromodulation in primary headaches: current evidence and integration into clinical practice. 61
32324707 2020
41
Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache. 61
32504377 2020
42
Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series. 61
32359106 2020
43
Patterns of pharmacological treatment of patients with migraine, tension-type headache, and cluster headache in a large group of patients in Colombia, 2019. 61
32541379 2020
44
Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis. 61
32293721 2020
45
Perceptions, experiences, and understandings of cluster headache among GPs and neurologists: a qualitative study. 61
32482627 2020
46
Sphenopalatine ganglion-targeted low-temperature plasma radiofrequency ablation in the treatment of refractory cluster headache. 61
32489492 2020
47
Determination of psychosocial factors in cluster headache - construction and psychometric properties of the Cluster Headache Scales (CHS). 61
32484060 2020
48
Evolving options for the treatment of cluster headache. 61
32209808 2020
49
Cluster headache therapies: pharmacology and mode of action. 61
32511056 2020
50
The impact of remission and coexisting migraine on anxiety and depression in cluster headache. 61
32471362 2020
Sources

Variations for Cluster Headache

About this section
Sources

Expression for Cluster Headache

About this section
Search GEO for disease gene expression data for Cluster Headache.
Sources

Pathways for Cluster Headache

About this section

Pathways related to Cluster Headache according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 12.64 VIP PNOC HCRTR2 CALCA ADCYAP1
2
Circadian entrainment 36
Show member pathways
 12 CLOCK CACNA1A ADCYAP1
3
G alpha (s) signalling events 65
10.96 VIP CALCA ADCYAP1
Sources

GO Terms for Cluster Headache

About this section

Cellular components related to Cluster Headache according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.43 VIP CALCA ADCYAP1
2 neuronal cell body GO:0043025 9.33 PNOC CALCA CACNA1A
3 cell GO:0005623 9.26 HCRTR2 CALCA CACNA1A ADCYAP1
4 terminal bouton GO:0043195 8.62 CALCA ADCYAP1

Biological processes related to Cluster Headache according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.72 VIP PNOC HCRTR2 CALCA ADCYAP1
2 chemical synaptic transmission GO:0007268 9.61 PNOC HCRTR2 CACNA1A
3 female pregnancy GO:0007565 9.55 PNOC ADCYAP1
4 regulation of insulin secretion GO:0050796 9.54 CLOCK CACNA1A
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.54 CALCA CACNA1A ADCYAP1
6 regulation of protein localization GO:0032880 9.52 VIP ADCYAP1
7 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.51 VIP HCRTR2
8 regulation of cytosolic calcium ion concentration GO:0051480 9.49 HCRTR2 CALCA
9 activation of adenylate cyclase activity GO:0007190 9.48 CALCA ADCYAP1
10 feeding behavior GO:0007631 9.46 HCRTR2 CALCA
11 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.43 VIP CALCA ADCYAP1
12 response to pain GO:0048265 9.4 CALCA CACNA1A
13 negative regulation of potassium ion transport GO:0043267 9.16 VIP ADCYAP1
14 positive regulation of blood vessel diameter GO:0097755 9.13 VIP CALCA ADCYAP1
15 neuropeptide signaling pathway GO:0007218 8.92 PNOC HCRTR2 CALCA ADCYAP1

Molecular functions related to Cluster Headache according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.33 VIP CALCA ADCYAP1
2 peptide hormone receptor binding GO:0051428 8.96 VIP ADCYAP1
3 neuropeptide hormone activity GO:0005184 8.8 VIP PNOC ADCYAP1
Sources

Sources for Cluster Headache

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....